Today announced plans to initiate a Stage 1 single-dose clinical trial of the businesss compound.

today announced plans to initiate a Stage 1 single-dose clinical trial of the business’s compound, Glial Growth Factor 2 , in patients with heart failing in mid-2010, based on an IND filed with the U.S. Meals and Drug Administration on March 19, 2010. GGF2 has been shown to safeguard heart muscle mass and restore cardiac function in preclinical models of heart failure, myocardial cardiotoxicity and infarction. An interview with Professor Lesley JonesMarriage status linked to survival outcomes following cardiac surgeryLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman’This IND may be the result of a number of years of analysis, preparing and collaboration. Acorda’s medical, preclinical and regulatory teams have done an outstanding job designing a advancement plan to explore the potential of GGF2 in heart failure,’ stated Ron Cohen, M.D., President and CEO of Acorda Therapeutics. Continue reading